Form Blends Semaglutide Review

Form Blends does one thing better than any other compounder we have reviewed, and it is the thing most of them get wrong. Our research (August 8, 2026) found exemplary evidence disclosure attached to a product menu that reaches past the evidence.

The Disclaimer Other Companies Should Copy

Form Blends cites the standard trial figures — average body-weight reduction over 72 weeks at the 15 mg weekly dose, and the share of semaglutide trial participants losing at least 10% of body weight — and then writes this:

"These figures are from controlled clinical trials of the FDA-approved branded medications (Wegovy, Zepbound), combined with diet and exercise. They are not outcomes for compounded products, for FormBlends specifically, or for any individual patient. Compounded medications are not FDA-approved. Individual results vary."

Read that against what we found elsewhere. EllieMD advertises "26%+ of initial body weight over 6-8 weeks." Trimi puts "Up to 22% weight loss" directly above "Compounded Tirzepatide." Form Blends names the branded products the data came from, names the diet-and-exercise component the trials included, and states explicitly that the numbers are not its own outcomes. That is three separate qualifications most of this industry omits. It is the correct way to cite trial evidence when selling a compounded copy.

Its Stated Operating Principles

Form Blends publishes a list of commitments: Independent Provider Review / State-Licensed Pharmacy Pathway / Evidence-Graded Content / Clear Product Status / Source-Level Citations / Patient-Specific Decisions. "Evidence-graded content" and "source-level citations" are unusual claims for this category, and the disclaimer above suggests they are not purely decorative.

Regulatory Basics

• All GLP-1 medications come from licensed 503A compounding pharmacies
• Coverage across 47 states
• Physician-guided care with independent provider review
• Compounded therapy dispensed by a licensed pharmacy, with product status stated plainly

Form Blends states the 503A pathway openly, which puts it ahead of Vios and Webster Pharmacy, though it stops short of naming the specific pharmacies the way Trimi does with license numbers, or publishing the accreditation and release-testing detail Pure Pharmacy provides.

Where the Menu Outruns the Standard

Having set a high bar on evidence, Form Blends then sells: NAD+ and sermorelin, described as "compounds studied for healthy aging." That phrasing is careful — "studied for" is not "shown to" — but these remain outside evidence-based practice for longevity or metabolic health. Peptide protocols more broadly, a category whose marketing claims consistently exceed published human evidence. Hair loss treatment using finasteride and minoxidil, which is different — both are genuinely evidence-backed for androgenetic alopecia, and offering them is unremarkable. The tension is specific: a company that goes out of its way to tell you trial data does not apply to its compounded GLP-1 also sells peptides for which there is barely any trial data to disclaim. The disclosure standard and the catalogue are not fully aligned.

What We Could Not Establish

No pricing was published in the material we reviewed. The specific compounding pharmacies are not named and no accreditation, third-party testing or beyond-use dating is published. The list of 47 states, eligibility criteria including BMI thresholds, dosing protocols and refund terms were also not available.